Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 107

1.

Sex Differences and Survival in Adults With Bicuspid Aortic Valves: Verification in 3 Contemporary Echocardiographic Cohorts.

Michelena HI, Suri RM, Katan O, Eleid MF, Clavel MA, Maurer MJ, Pellikka PA, Mahoney D, Enriquez-Sarano M.

J Am Heart Assoc. 2016 Sep 29;5(10). pii: e004211.

2.

In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.

AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, Swisher EM, Kaufmann SH, Haluska P.

Gynecol Oncol. 2016 Nov;143(2):379-388. doi: 10.1016/j.ygyno.2016.08.328.

PMID:
27614696
3.

Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.

Maurer MJ, Bachy E, Ghesquières H, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Allmer C, Chassagne-Clément C, Nicolas-Virelizier E, Sebban C, Lebras L, Sarkozy C, Macon WR, Feldman AL, Syrbu SI, Traverse-Glehan A, Coiffier B, Slager SL, Weiner GJ, Witzig TE, Habermann TM, Salles G, Cerhan JR, Link BK.

Am J Hematol. 2016 Nov;91(11):1096-1101. doi: 10.1002/ajh.24492.

PMID:
27465588
4.

A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts.

Ghesquières H, Larrabee BR, Casasnovas O, Maurer MJ, McKay JD, Ansell SM, Montgomery D, Asmann YW, Farrell K, Verney A, Slager SL, Allmer C, Perrot A, Delarue R, Habermann TM, Dupuis J, Link BK, Canioni D, Dogan A, Cozen W, Jarrett RF, Cerhan JR, Salles G.

Br J Haematol. 2016 Sep 9. doi: 10.1111/bjh.14306. [Epub ahead of print] No abstract available.

PMID:
27716907
5.

Brain potentials predict substance abuse treatment completion in a prison sample.

Fink BC, Steele VR, Maurer MJ, Fede SJ, Calhoun VD, Kiehl KA.

Brain Behav. 2016 May 31;6(8):e00501. doi: 10.1002/brb3.501.

6.

FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.

Ghesquières H, Larrabee BR, Haioun C, Link BK, Verney A, Slager SL, Ketterer N, Ansell SM, Delarue R, Maurer MJ, Fitoussi O, Habermann TM, Peyrade F, Dogan A, Molina TJ, Novak AJ, Tilly H, Cerhan JR, Salles G.

Hematol Oncol. 2016 Jun 10. doi: 10.1002/hon.2305. [Epub ahead of print]

PMID:
27282998
7.

Degradation Signals for Ubiquitin-Proteasome Dependent Cytosolic Protein Quality Control (CytoQC) in Yeast.

Maurer MJ, Spear ED, Yu AT, Lee EJ, Shahzad S, Michaelis S.

G3 (Bethesda). 2016 Jul 7;6(7):1853-66. doi: 10.1534/g3.116.027953.

8.

Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia.

Parry HM, Damery S, Hudson C, Maurer MJ, Cerhan JR, Pachnio A, Begum J, Slager SL, Fegan C, Man S, Pepper C, Shanafelt TD, Pratt G, Moss PA.

Am J Hematol. 2016 Aug;91(8):776-81. doi: 10.1002/ajh.24403.

9.

Gene Amplification on Demand Accelerates Cellobiose Utilization in Engineered Saccharomyces cerevisiae.

Oh EJ, Skerker JM, Kim SR, Wei N, Turner TL, Maurer MJ, Arkin AP, Jin YS.

Appl Environ Microbiol. 2016 May 31;82(12):3631-9. doi: 10.1128/AEM.00410-16.

10.

APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.

Leonard B, Starrett GJ, Maurer MJ, Oberg AL, Van Bockstal M, Van Dorpe J, De Wever O, Helleman J, Sieuwerts AM, Berns EM, Martens JW, Anderson BD, Brown WL, Kalli KR, Kaufmann SH, Harris RS.

Clin Cancer Res. 2016 Sep 15;22(18):4746-55. doi: 10.1158/1078-0432.CCR-15-2910.

PMID:
27016308
11.

Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma.

Maurer MJ, Jais JP, Ghesquières H, Witzig TE, Hong F, Haioun C, Thompson CA, Thieblemont C, Micallef IN, Porrata LF, Ribrag V, Nowakowski GS, Casasnovas O, Bologna S, Morschhauser F, Morrison VA, Peterson BA, Macon WR, Copie-Bergman C, Feldman AL, Syrbu SI, Kurtin PJ, Gascoyne RD, Li H, Allmer C, Kahl BS, Ansell SM, Slager SL, Link BK, Salles G, Habermann TM, Tilly H, Cerhan JR.

Am J Hematol. 2016 Feb;91(2):179-84. doi: 10.1002/ajh.24223.

12.

Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma.

Gupta M, Stenson M, O'Byrne M, Maurer MJ, Habermann T, Cerhan JR, Weiner GW, Witzig TE.

Ann Oncol. 2016 Jan;27(1):165-72. doi: 10.1093/annonc/mdv486.

PMID:
26487586
13.

Engineering Rhodosporidium toruloides for increased lipid production.

Zhang S, Skerker JM, Rutter CD, Maurer MJ, Arkin AP, Rao CV.

Biotechnol Bioeng. 2016 May;113(5):1056-66. doi: 10.1002/bit.25864.

PMID:
26479039
14.

Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.

Ghesquieres H, Slager SL, Jardin F, Veron AS, Asmann YW, Maurer MJ, Fest T, Habermann TM, Bene MC, Novak AJ, Mareschal S, Haioun C, Lamy T, Ansell SM, Tilly H, Witzig TE, Weiner GJ, Feldman AL, Dogan A, Cunningham JM, Olswold CL, Molina TJ, Link BK, Milpied N, Cox DG, Salles GA, Cerhan JR.

J Clin Oncol. 2015 Nov 20;33(33):3930-7. doi: 10.1200/JCO.2014.60.2573.

15.

Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers.

Mehner C, Oberg AL, Kalli KR, Nassar A, Hockla A, Pendlebury D, Cichon MA, Goergen KM, Maurer MJ, Goode EL, Keeney GL, Jatoi A, Sahin-Tóth M, Copland JA, Radisky DC, Radisky ES.

Oncotarget. 2015 Nov 3;6(34):35737-54. doi: 10.18632/oncotarget.5927.

16.

Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma.

Novak AJ, Asmann YW, Maurer MJ, Wang C, Slager SL, Hodge LS, Manske M, Price-Troska T, Yang ZZ, Zimmermann MT, Nowakowski GS, Ansell SM, Witzig TE, McPhail E, Ketterling R, Feldman AL, Dogan A, Link BK, Habermann TM, Cerhan JR.

Blood Cancer J. 2015 Aug 28;5:e346. doi: 10.1038/bcj.2015.69.

17.

Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.

Knutson KL, Maurer MJ, Preston CC, Moysich KB, Goergen K, Hawthorne KM, Cunningham JM, Odunsi K, Hartmann LC, Kalli KR, Oberg AL, Goode EL.

Cancer Immunol Immunother. 2015 Dec;64(12):1495-504. doi: 10.1007/s00262-015-1753-x.

18.

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW.

J Clin Oncol. 2015 Aug 10;33(23):2516-22. doi: 10.1200/JCO.2014.59.7534. Erratum in: J Clin Oncol. 2016 Apr 20;34(12):1430.

19.

Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011.

Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS.

Am J Hematol. 2015 Sep;90(9):790-5. doi: 10.1002/ajh.24086.

20.

Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States.

Nabhan C, Byrtek M, Rai A, Dawson K, Zhou X, Link BK, Friedberg JW, Zelenetz AD, Maurer MJ, Cerhan JR, Flowers CR.

Br J Haematol. 2015 Jul;170(1):85-95. doi: 10.1111/bjh.13399.

Items per page

Supplemental Content

Loading ...
Support Center